Jinan Zhuocheng Bio-Tech Co., Ltd.

I. Specialized Division of Labor in the Three-Tier Global Veterinary Pharmaceutical Landscape

The global veterinary pharmaceutical industry is following the “three-pole dominance, multi-point development” pattern of human pharmaceuticals, forming a differentiated division of labor. The North American cluster, centered on Greenfield, Indiana (Elanco headquarters), New Jersey, and Kansas, relies on leading companies such as MSD Animal Health and Zoetis, maintaining global leadership in companion animal drugs, vaccine adjuvants, and digital disease surveillance. The European cluster, anchored by Leverkusen, Germany (Bayer Animal Health), Lyon, France (Virbac), and Boxmeer, the Netherlands (MSD Animal Health Europe Center), focuses on ruminant health products, aquaculture drugs, and antibiotic alternative therapies. The EU EMA Veterinary Committee’s “antibiotic reduction roadmap” has driven the world’s strictest veterinary drug residue standards and an innovation ecosystem for alternative products. The East Asian cluster, represented by Japan’s Musashino Animal Health Research City, Shanghai Oriental Beauty Valley Veterinary Drug Park, Beijing Daxing Biopharmaceutical Base veterinary segment, and Suzhou BioBAY Veterinary Biologics Sub-park, focuses on breakthroughs in pet monoclonal antibodies, African swine fever genetic engineering vaccines, and modernization of traditional veterinary medicine. In addition, India’s Hyderabad Gene Valley has formed the world’s largest API and veterinary generic drug export system, while Singapore’s Biopolis has emerged as a regional distribution and clinical trial center for veterinary biologics in Southeast Asia, leveraging its cold-chain logistics hub advantages.

II. From Strategic Guidance to Institutional Innovation: Precision Policy Support for the Veterinary Pharmaceutical Industry

Major economies have established differentiated policy support systems for the veterinary pharmaceutical industry. The United States, through the FDA Center for Veterinary Medicine (CVM), the Animal Drug User Fee Amendments (ADUFA), and the Minor Use/Minor Species (MUMS) orphan drug program, has significantly shortened the approval cycle for generic veterinary drugs and granted 7-year market exclusivity for minor-use indications, directly stimulating R&D pipelines of veterinary startups in the Boston–Cambridge area. The European Union, through the European Animal Health Innovation Partnership (EPIAH), supported by low-interest loans from the European Investment Bank, promotes cross-border collaborative R&D in vaccine adjuvants, long-acting injectables, and antibiotic-reduction feed additives. Germany’s Federal Ministry of Food and Agriculture has also established an “Antimicrobial Reduction Innovation Fund,” providing up to 40% post-development reimbursement of total R&D costs for new veterinary drugs validated through “farm-to-fork” clinical trials. China, under the framework of the “14th Five-Year National Action Plan for Reducing Veterinary Antibiotic Use,” has implemented differentiated initiatives in Beijing, Shanghai, Suzhou, and Shenzhen. The Beijing Municipal Agriculture and Rural Affairs Bureau, together with the Municipal Science and Technology Commission, launched the “Veterinary Drug Innovation Open Competition (Rally-the-Troops Program),” providing milestone-based funding for projects such as pet oncology monoclonal antibodies and long-acting antiparasitics for ruminants, and pioneered a mutual recognition mechanism for veterinary biologics clinical ethics review, reducing multi-center trial initiation time by nearly half. Suzhou Industrial Park introduced a tiered subsidy system for R&D investment: companies obtaining Class I new veterinary drug certificates and industrializing them in the park receive up to RMB 8 million, RMB 12 million, and RMB 20 million in support for Phase I, II, and III clinical trials respectively, while also opening public biopharmaceutical pilot platforms to provide GMP-level production services for veterinary mRNA vaccines. Shenzhen focuses on cross-border veterinary collaboration through the “Greater Bay Area Veterinary Innovation Talent Program,” attracting overseas returnee teams and providing “plug-and-play” access from laboratories to P3 animal testing facilities, while piloting cross-border clinical data mutual recognition to reduce regulatory costs for Hong Kong, Macau, and international veterinary products entering mainland China.

III. Full-Chain Incubation and Reverse Empowerment from the Sales End

Leading veterinary clusters are transferring incubation experience from human pharmaceuticals into the veterinary sector while strengthening the unique mechanism of reverse empowerment from the sales channel. Incubation side: Belgium’s Wallonia SPARSH program, modeled after LabCentral, operates shared biosafety level 2 (BSL-2) poultry and swine experimental facilities, supported by a European veterinary CRO network, enabling startups to complete the process from target validation to candidate compound screening within six months. The Suzhou BioBAY Veterinary Sub-park, in collaboration with the China Institute of Veterinary Drug Control, has built China’s first public evaluation center for veterinary biologics, reducing testing costs for monoclonal antibody purity and viral neutralization assays to 30% of market rates, while also providing GMP-compliant pilot-scale facilities for veterinary drugs. Sales side: The Boxmeer Animal Health Center in the Netherlands adopts a “virtual sales hub” model, connecting resident companies with Europe’s top three veterinary wholesalers and retail pharmacy chains, using a standardized regulatory and documentation repository to shorten EU distribution access time for startups by nearly 50%. The joint commercial accelerator established by Zoetis and Elanco in Indiana provides a dual incentive mechanism of “R&D milestones + sales channel access,” allowing approved products to directly enter global distribution networks of the two leading companies, with dynamically adjusted first-year revenue sharing ratios. Beijing Daxing Biopharmaceutical Base has also established a digital closed-loop system of “prescription flow-out to pharmacy delivery” with JD Health Pet Hospitals and New Ruipeng Pet Medical Group, enabling pet drugs developed by companies in the park to complete first-order delivery via online prescriptions, significantly shortening commercialization validation cycles. From geographic clustering to ecosystem co-prosperity, emerging trends indicate that AI-assisted veterinary target discovery, cloud-based remote animal clinical trial management, and blockchain-based cross-border traceability systems are reshaping the competitive logic of veterinary clusters. In the future, clusters that first achieve rapid translation of cutting-edge human pharmaceutical technologies (such as mRNA, ADC, and gene editing) into veterinary applications, establish international regulatory mutual recognition under the “One Health” framework, and integrate end-to-end data loops from R&D to sales will dominate the next wave of global veterinary pharmaceutical growth.